Protara Therapeutics Inc. 正稳步推进其临床开发计划,目标是在2026年下半年,针对BCG初治患者群体,启动其关键的Advanced-3注册试验。这一进展标志着公司在推进其候选疗法方面迈出了重要一步。
Protara Therapeutics Inc. 正稳步推进其临床开发计划,目标是在2026年下半年,针对BCG初治患者群体,启动其关键的Advanced-3注册试验。这一进展标志着公司在推进其候选疗法方面迈出了重要一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.